Strategies for Glycoengineering Therapeutic Proteins
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Almost all therapeutic proteins are glycosylated, with the carbohydrate component playing a long-established, substantial role in the safety and pharmacokinetic properties of this dominant category of drugs. In the past few years and moving forward, glycosylation is increasingly being implicated in the pharmacodynamics and therapeutic efficacy of therapeutic proteins. This article provides illustrative examples of drugs that have already been improved through glycoengineering including cytokines exemplified by erythropoietin (EPO), enzymes (ectonucleotide pyrophosphatase 1, ENPP1), and IgG antibodies (e.g., afucosylated Gazyva®, Poteligeo®, Fasenra™, and Uplizna®). In the future, the deliberate modification of therapeutic protein glycosylation will become more prevalent as glycoengineering strategies, including sophisticated computer-aided tools for “building in” glycans sites, acceptance of a broad range of production systems with various glycosylation capabilities, and supplementation methods for introducing non-natural metabolites into glycosylation pathways further develop and become more accessible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
CHARMM‐GUI: A web‐based graphical user interface for CHARMM
Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008) · Journal of Computational Chemistry · doi:10.1002/jcc.20945 · Cited by 9,284 · cited 2×
“present N-glycan structures via CHARMM (Jo et al., 2008) and PyMOL (PyMOL Molecular Graphics System, Version 2.”
MethodInfluentialAntibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Intracellular Functions of N-Linked Glycans
Helenius, A., & Aebi, A. M. (2001) · Science · doi:10.1126/science.291.5512.2364 · Cited by 2,405
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849 · cited 1×
“In some cases, the IgG is pretreated with neuraminidase to remove non-inflammatory α2,3sialic acids and, in other cases, the sialylation reaction is done in the presence of β1,4-galactosyltransferase and UDP-galactose to install the penultimate galactose required for terminal sialylation (Anthony et al., 2008; Washbur…”
BackgroundAdvances in protein structure prediction and design
Kuhlman, B., & Bradley, P. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0163-x · Cited by 806
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Research works printed but not linked: 233
- Abu-Qarn, 2008, Not just for Eukarya Anymore: Protein Glycosylation in Bacteria and Archaea, Curr. Opin. Struct. Biol., 18, 544, 10.1016/j.sbi.2008.06.010 · DOI · Paper page
- Ackerman, 2013, Natural Variation in Fc Glycosylation of HIV-specific Antibodies Impacts Antiviral Activity, J. Clin. Invest., 123, 2183, 10.1172/jci65708 · DOI · Paper page
- Agatemor, 2019, Exploiting Metabolic Glycoengineering to advance Healthcare, Nat. Rev. Chem., 3, 605, 10.1038/s41570-019-0126-y · DOI · Paper page
- Agatemor, 2021, Imaging Glycans with Metabolic Glycoengineering, 253
- Aich, 2008, Regioisomeric SCFA Attachment to Hexosamines Separates Metabolic Flux from Cytotoxicity and MUC1 Suppression, ACS Chem. Biol., 3, 230, 10.1021/cb7002708 · DOI
- Ailor, 2000, N-glycan Patterns of Human Transferrin Produced in Trichoplusia Ni Insect Cells: Effects of Mammalian Galactosyltransferase, Glycobiology, 10, 837, 10.1093/glycob/10.8.837 · DOI
- Albright, 2015, ENPP1-Fc Prevents Mortality and Vascular Calcifications in Rodent Model of Generalized Arterial Calcification of Infancy, Nat. Commun., 6, 10006, 10.1038/ncomms10006 · DOI · Paper page
- Almaraz, 2012, Metabolic Oligosaccharide Engineering with N-Acyl Functionalized ManNAc Analogs: Cytotoxicity, Metabolic Flux, and Glycan-Display Considerations, Biotechnol. Bioeng., 109, 992, 10.1002/bit.24363 · DOI
- Alter, 2018, Antibody Glycosylation in Inflammation, Disease and Vaccination, Semin. Immunol., 39, 102, 10.1016/j.smim.2018.05.003 · DOI · Paper page
- Alves, 2016, Human Carboxylesterase 2: Studies on the Role of Glycosylation for Enzymatic Activity, Biochem. Biophys. Rep., 5, 105, 10.1016/j.bbrep.2015.11.018 · DOI
- Arena de Souza, 2015, Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1, PLoS One, 10, e0143919, 10.1371/journal.pone.0143919 · DOI
- Ayoub, 2013, Correct Primary Structure Assessment and Extensive Glyco-Profiling of Cetuximab by a Combination of Intact, Middle-Up, Middle-Down and Bottom-Up ESI and MALDI Mass Spectrometry Techniques, mAbs, 5, 699, 10.4161/mabs.25423 · DOI · Paper page
- Barahona Afonso, 2016, The Production Processes and Biological Effects of Intravenous Immunoglobulin, Biomolecules, 6, 15, 10.3390/biom6010015 · DOI
- Bartsch, 2018, Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis, Front. Immunol., 9, 1183, 10.3389/fimmu.2018.01183 · DOI
- Baskin, 2007, Copper-free Click Chemistry for Dynamic In Vivo Imaging, Proc. Natl. Acad. Sci. U.S.A., 104, 16793, 10.1073/pnas.0707090104 · DOI · Paper page
- Beck, 2010, GlycoFi's Technology to Control the Glycosylation of Recombinant Therapeutic Proteins, Expert Opin. Drug Discov., 5, 95, 10.1517/17460440903413504 · DOI · Paper page
- Bencharit, 2003, Crystal Structure of Human Carboxylesterase 1 Complexed with the Alzheimer's Drug Tacrine, Chem. Biol., 10, 341, 10.1016/s1074-5521(03)00071-1 · DOI · Paper page
- Boekhout, 2011, Trastuzumab, Tratuzumab. Oncologist., 16, 800, 10.1634/theoncologist.2010-0035 · DOI
- Bork, 2009, Increasing the Sialylation of Therapeutic Glycoproteins: the Potential of the Sialic Acid Biosynthetic Pathway, J. Pharm. Sci., 98, 3499, 10.1002/jps.21684 · DOI · Paper page
- Boune, 2020, Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations, Antibodies, 9, 22, 10.3390/antib9020022 · DOI
- Boyce, 2011, Metabolic Cross-Talk Allows Labeling of O-Linked β- N -Acetylglucosamine-Modified Proteins via the N -acetylgalactosamine Salvage Pathway, Proc. Natl. Acad. Sci. U.S.A., 108, 3141, 10.1073/pnas.1010045108 · DOI · Paper page
- Breitfeld, 1984, Influence of the N-Linked Oligosaccharides on the Biosynthesis, Intracellular Routing, and Function of the Human Asialoglycoprotein Receptor, J. Biol. Chem., 259, 10414, 10.1016/s0021-9258(18)90980-4 · DOI · Paper page
- Brumshtein, 2010, Characterization of Gene-Activated Human Acid- -glucosidase: Crystal Structure, Glycan Composition, and Internalization into Macrophages, Glycobiology, 20, 24, 10.1093/glycob/cwp138 · DOI
- Buettner, 2018, Improving Immunotherapy through Glycodesign, Front. Immunol., 9, 2485, 10.3389/fimmu.2018.02485 · DOI
- Burgdorf, 2006, The Mannose Receptor Mediates Uptake of Soluble but Not of Cell-Associated Antigen for Cross-Presentation, J. Immunol., 176, 6770, 10.4049/jimmunol.176.11.6770 · DOI · Paper page
- Burkhart, 2006, Design, Synthesis, and Preliminary Evaluation of Doxazolidine Carbamates as Prodrugs Activated by Carboxylesterases, J. Med. Chem., 49, 7002, 10.1021/jm060597e · doi:10.1021/jm060597e
- Burnett, 2020, Therapeutic Recombinant Protein Production in Plants: Challenges and Opportunities, Plants People Planet., 2, 121, 10.1002/ppp3.10073 · DOI · Paper page
- Casalino, 2020, Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein, ACS Cent. Sci., 6, 1722, 10.1021/acscentsci.0c01056 · DOI · Paper page
- Castilho, 2012, Glyco-engineering in Plants to Produce Human-like N-Glycan Structures, Biotechnol. J., 7, 1088, 10.1002/biot.201200032 · DOI
- Chitlaru, 1998, Modulation of Circulatory Residence of Recombinant Acetylcholinesterase through Biochemical or Genetic Manipulation of Sialylation Levels, Biochem. J, 336, 647, 10.1042/bj3360647 · DOI
- Cobb, 2020, The History of IgG Glycosylation and where We Are Now, Glycobiology, 30, 202, 10.1093/glycob/cwz065 · DOI · Paper page
- Contreras-Gómez, 2014, Protein Production Using the Baculovirus-Insect Cell Expression System, Biotechnol. Prog., 30, 1, 10.1002/btpr.1842 · DOI · Paper page
- Cowper, 2018, Comprehensive Glycan Analysis of Twelve Recombinant Human Erythropoietin Preparations from Manufacturers in China and Japan, J. Pharm. Biomed. Anal., 153, 214, 10.1016/j.jpba.2018.02.043 · DOI
- Cox, 2009, FluBlok, a Next Generation Influenza Vaccine Manufactured in Insect Cells, Biologicals, 37, 182, 10.1016/j.biologicals.2009.02.014 · DOI · Paper page
- Cox, 2012, Imiglucerase in the Treatment of Gaucher Disease: a History and Perspective, Dddt, 6, 81, 10.2147/DDDT.S14395 · DOI
- Davis, 2014, Naturally Occurring Follicle-Stimulating Hormone Glycosylation Variants, J. Glycomics Lipidomics, 4, e117, 10.4172/2153-0637.1000e117 · doi:10.4172/2153-0637.1000e117
- Daya, 2004, Follicle-stimulating Hormone in Clinical Practice, Treatments Endocrinol., 3, 161, 10.2165/00024677-200403030-00004 · DOI
- De Wachter, 2018, Engineering of Yeast Glycoprotein Expression, Adv. Biochem. Eng. Biotechnol., 175, 93, 10.1007/10_2018_69 · DOI
- Dias, 2021, New Human Follitropin Preparations: How Glycan Structural Differences May Affect Biochemical and Biological Function and Clinical Effect, Front. Endocrinol., 12, 636038, 10.3389/fendo.2021.636038 · DOI
- Ding, 2019, Improving Production of N-Glycosylated Recombinant Proteins by Leaky Escherichia coli, 3 Biotech., 9, 302, 10.1007/s13205-019-1830-5 · doi:10.1007/s13205-019-1830-5
- Drake, 2014, Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct In Vivo Efficacy and PK Outcomes, Bioconjug. Chem., 25, 1331, 10.1021/bc500189z · DOI · Paper page
- Du, 2021, Glycoengineering Human Neural and Adipose Stem Cells with Novel Thiol-Modified N-Acetylmannosamine (ManNAc) Analogs, Cells, 10, 377377, 10.3390/cells10020377 · DOI
- Du, 2022, Glycoengineering Human Neural Stem Cells (hNSCs) for Adhesion Improvement Using a Novel Thiol-Modified N-Acetylmannosamine (ManNAc) Analog, Mater. Sci. Eng. C, 2022, 112675, 10.1016/j.msec.2022.112675 · DOI
- Du, 2009, Metabolic Glycoengineering: Sialic Acid and beyond, Glycobiology, 19, 1382, 10.1093/glycob/cwp115 · DOI · Paper page
- Dwek, 2002, Introduction: GlycobiologyUnderstanding the Language and Meaning of Carbohydrates, Chem. Rev., 102, 283, 10.1021/cr010385j · doi:10.1021/cr010385j
- Dwek, 1996, Glycobiology: Toward Understanding the Function of Sugars, Chem. Rev., 96, 683, 10.1021/10.1021/cr940283b · doi:10.1021/10.1021/cr940283b
- Egrie, 2002, Development and Characterization of Darbepoetin Alfa, Oncology (Williston Park), 16, 13
- Ellies, 2002, Sialyltransferase ST3Gal-IV Operates as a Dominant Modifier of Hemostasis by Concealing Asialoglycoprotein Receptor Ligands, Proc. Natl. Acad. Sci. U.S.A., 99, 10042, 10.1073/pnas.142005099 · DOI · Paper page
- Elliot, 2000, Rational Design of Novel Erythropoiesis Stimulating Protein (AranespTM): a Super-sialylated Molecule with Increased Biological Activity, Blood, 96
- Elliott, 2008, Erythropoietins: A Common Mechanism of Action, Exp. Hematol., 36, 1573, 10.1016/j.exphem.2008.08.003 · DOI · Paper page
- Feinberg, 2021, Structural Analysis of Carbohydrate Binding by the Macrophage Mannose Receptor CD206, J. Biol. Chem., 296, 100368, 10.1016/j.jbc.2021.100368 · DOI
- Ferreira, 2021, Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies, J. Bone Miner. Res., 36, 2193, 10.1002/jbmr.4418 · DOI
- Fischer, 2018, Glyco-engineering of Plant-Based Expression Systems, Adv. Biochem. Eng. Biotechnol., 175, 137, 10.1007/10_2018_76 · DOI
- Fleming, 2005, Structural Insights into Drug Processing by Human Carboxylesterase 1: Tamoxifen, Mevastatin, and Inhibition by Benzil, J. Mol. Biol., 352, 165, 10.1016/j.jmb.2005.07.016 · DOI
- Fleming, 2007, Crystal Structures of Human Carboxylesterase 1 in Covalent Complexes with the Chemical Warfare Agents Soman and Tabun,, Biochemistry, 46, 5063, 10.1021/bi700246n · DOI
- Fox, 2021, A Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis, Mult. Scler., 27, 420, 10.1177/1352458520918375 · DOI
- Fox, 2012, First Plant-Made Biologic Approved, Nat. Biotechnol., 30, 472, 10.1038/nbt0612-472 · DOI
- Friedman, 1999, A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived β-Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease, Blood, 93, 2807, 10.1182/blood.v93.9.2807.409k08_2807_2816 · doi:10.1182/blood.v93.9.2807.409k08_2807_2816
- Friedman, 2008, A Southern Mystery., 26526
- Fukami, 2012, The Emerging Role of Human Esterases, Drug Metab. Pharmacokinet., 27, 466, 10.2133/dmpk.dmpk-12-rv-042 · DOI · Paper page
- Gazi, 2009, Influence of the Mannose Receptor in Host Immune Responses, Immunobiology, 214, 554, 10.1016/j.imbio.2008.11.004 · DOI · Paper page
- Geisler, 2015, An Overview and History of Glyco-Engineering in Insect Expression Systems, 131
- Giddens, 2018, Site-selective Chemoenzymatic Glycoengineering of Fab and Fc Glycans of a Therapeutic Antibody, Proc. Natl. Acad. Sci. U.S.A., 115, 12023, 10.1073/pnas.1812833115 · DOI
- Go, 2017, Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers, J. Virol., 91, e02428-02416, 10.1128/jvi.02428-16 · DOI
- Golay, 2013, Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis through CD16B More Efficiently Than Rituximab, Blood, 122, 3482, 10.1182/blood-2013-05-504043 · DOI · Paper page
- Gong, 2021, The Glycosylation in SARS-CoV-2 and its Receptor ACE2, Signal. Transduct. Target. Ther., 6, 396, 10.1038/s41392-021-00809-8 · DOI · Paper page
- Greig, 2002, Butyrylcholinesterase: an Important New Target in Alzheimer's Disease Therapy, Int. Psychogeriatr, 14, 77, 10.1017/s1041610203008676 · DOI · Paper page
- Grimsey, 2020, The Effect of Lipidation and Glycosylation on Short Cationic Antimicrobial Peptides, Biochim. Biophys. Acta Biomem., 1862, 183195, 10.1016/j.bbamem.2020.183195 · DOI
- Gross, 1988, Enzymatic Introduction of a Fluorescent Sialic Acid into Oligosaccharide Chains of Glycoproteins, Eur. J. Biochem., 177, 583, 10.1111/j.1432-1033.1988.tb14410.x · doi:10.1111/j.1432-1033.1988.tb14410.x
- Gross, 1995, Enzymatic Transfer of Sialic Acids Modified at C-5 Employing Four Different Sialyltransferases, Glycoconj. J., 12, 739, 10.1007/BF00731233 · doi:10.1007/bf00731233
- Gross, 1989, Transfer of Synthetic Sialic Acid Analogues to N- and O-Linked Glycoprotein Glycans Using Four Different Mammalian Sialyltransferases, Biochemistry, 28, 7386, 10.1021/bi00444a036 · doi:10.1021/bi00444a036
- Guan, 2018, Chemically Precise Glycoengineering Improves Human Insulin, ACS Chem. Biol., 13, 73, 10.1021/acschembio.7b00794 · DOI
- Gupta, 2002, Prediction of Glycosylation across the Human Proteome and the Correlation to Protein Function, Pac. Symp. Biocomputing, 7, 310
- Hamilton, 2015, Progress in Yeast Glycoengineering, 73, 10.1007/978-1-4939-2760-9_6 · DOI
- Heß, 2019, Glycosylation of HIV Env Inpacts IgG Subtype Responses to Vaccination, Viruses, 11, 153, 10.3390/v11020153 · DOI
- Higashiyama, 2018, Chemo-enzymatic Synthesis of the Glucagon Containing N-Linked Oligosaccharide and its Characterization, Carbohydr. Res., 455, 92, 10.1016/j.carres.2017.11.007 · doi:10.1016/j.carres.2017.11.007
- Hokke, 1990, Sialylated Carbohydrate Chains of Recombinant Human Glycoproteins Expressed in Chinese Hamster Ovary Cells Contain Traces of N-Glycolylneuraminic Acid, FEBS Lett., 275, 9, 10.1016/0014-5793(90)81427-P · DOI · Paper page
- Hollister, 1988, Stable Expression of Mammalian B1,4-Galactosyltransferase Extends the N-Glycosylation Pathway in Insect Cells, Glycobiology, 8, 473, 10.1093/glycob/8.5.473 · DOI
- Hong, 2010, Labeling Live Cells by Copper-Datalyzed Alkyne-Azide Click Chemistry, Bioconjug. Chem., 21, 1912, 10.1021/bc100272z · DOI · Paper page
- Hurjak, 2020, N-glycosylation of Blood Coagulation Factor XIII Subunit B and its Functional Consequence, J. Thromb. Haemost., 18, 1302, 10.1111/jth.14792 · doi:10.1111/jth.14792
- Ichikawa, 2018, Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of Glucagon-like Peptide-1, ACS Omega, 3, 5346, 10.1021/acsomega.8b00467 · DOI
- Irvine, 2020, Understanding the Role of Antibody Glycosylation through the Lens of Severe Viral and Bacterial Diseases, Glycobiology, 30, 241, 10.1093/glycob/cwaa018 · DOI
- Jain, 2012, A Review of Glycosylated Carriers for Drug Delivery, Biomaterials, 33, 4166, 10.1016/j.biomaterials.2012.02.033 · DOI · Paper page
- Janin-Bussat, 2013, Cetuximab Fab and Fc N-Glycan Fast Characterization Using IdeS Digestion and Liquid Chromatography Coupled to Electrospray Ionization Mass Spectrometry, Methods Mol. Biol., 988, 93, 10.1007/978-1-62703-327-5_7 · DOI
- Ji, 2017, New Insights into Influenza A Specificity: an Evolution of Paradigms, Curr. Opin. Struct. Biol., 44, 219, 10.1016/j.sbi.2017.06.001 · DOI
- Johnson, 2013, The Regulatory Power of Glycans and Their Binding Partners in Immunity, Trends Immunol., 34, 290, 10.1016/j.it.2013.01.006 · DOI · Paper page
- Jones, 2016, B-cell–independent Sialylation of IgG, Proc. Natl. Acad. Sci. U. S. A., 11, 7207, 10.1073/pnas.1523968113 · DOI
- Jones, 2004, Characterization of the Cellular Uptake and Metabolic Conversion of Acetylated N-Acetylmannosamine (ManNAc) Analogues to Sialic Acids, Biotechnol. Bioeng., 85, 394, 10.1002/bit.10901 · doi:10.1002/bit.10901
- Joshi, 2001, Production of a Sialylated N-Linked Glycoprotein in Insect Cells, Biotechnol. Prog., 17, 822, 10.1021/bp010071h · doi:10.1021/bp010071h
- Jourdian, 1971, The Sialic Acids. XI. A Periodate-Resorcinol Method for the Quantitative Estimation of Free Sialic Acids and Their Glycosides, J. Biol. Chem., 246, 430, 10.1016/s0021-9258(18)62508-6 · DOI · Paper page
- Kamber, 2019, Isomeric Triazines Exhibit Unique Profiles of Bioorthogonal Reactivity, Chem. Sci., 10, 9109, 10.1039/c9sc01427f · doi:10.1039/c9sc01427f
- Karki, 2021, Cellular Engineering of Plant Cells for Improved Therapeutic Protein Production, Plant Cell Rep., 40, 1087, 10.1007/s00299-021-02693-6 · DOI
- Kayser, Incorporation of N-Acyl-2-Amino-2-Deoxy-Hexoses into Glycosphingolipids of the Pheochromocytoma Cell Line PC 12, FEBS Lett., 301, 137, 10.1016/0014-5793(92)81233-c · doi:10.1016/0014-5793(92)81233-c
- Kayser, Biosynthesis of a Nonphysiological Sialic Acid in Different Rat Organs, Using N-Propanoyl-D-Hexosamines as Precursors, J. Biol. Chem., 267, 16934, 10.1016/s0021-9258(18)41874-1 · DOI · Paper page
- Keppler, 2001, Biochemical Engineering of the N-Acyl Side Chain of Sialic Acid: Biological Implications, Glycobiology, 11, 11R, 10.1093/glycob/11.2.11R · DOI · Paper page
- Kim, 2004, Characterization of the Metabolic Flux and Apoptotic Effects of O-Hydroxyl- and N-Acetylmannosamine (ManNAc) Analogs in Jurkat (Human T-Lymphoma-Derived) Cells, J. Biol. Chem., 279, 18342, 10.1074/jbc.M400205200 · DOI
- Kim, 2002, Expression of a Functional Drosophila melanogaster N-Acetylneuraminic Acid (Neu5Ac) Phosphate Synthase Gene: Evidence for Endogneous Sialic Acid Biosynthetic Ability in Insects, Glycobiology, 12, 73, 10.1093/glycob/12.2.73 · DOI
- Kohi, 2016, Hyaluromycin, a Novel Hyaluronidase Inhibitor, Attenuates Pancreatic Cancer Cell Migration and Proliferation, J. Oncol., 2016, 9063087, 10.1155/2016/9063087 · DOI
- Kolarich, 2008, Glycoproteomic Characterization of Butyrylcholinesterase from Human Plasma, Proteomics, 8, 254, 10.1002/pmic.200700720 · DOI
- Kolbeck, 2010, MEDI-563, a Humanized anti-IL-5 Receptor Alpha mAb with Enhanced Antibody-dependent Cell-Mediated Cytotoxicity Function, J. Allergy Clin. Immunol., 125, 1344, 10.1016/j.jaci.2010.04.004 · DOI · Paper page
- Kosloski, 2009, Role of Glycosylation in Conformational Stability, Activity, Macromolecular Interaction and Immunogenicity of Recombinant Human Factor VIII, AAPS J., 11, 424, 10.1208/s12248-009-9119-y · DOI
- Kotsovilis, 2014, Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases, Methods Mol. Biol., 1016, 37, 10.1007/978-1-62703-586-6_3 · DOI
- Kroetz, 1993, Glycosylation-dependent Activity of Baculovirus-Expressed Human Liver Carboxylesterases: cDNA Cloning and Characterization of Two Highly Similar Enzyme Forms, Biochemistry, 32, 11606, 10.1021/bi00094a018 · DOI
- Kulagine, 2021, Yeasts as Biopharmaceutical Production Platforms, Front. Fungal Biol., 2, 733492, 10.3389/ffunb.2021.733492 · DOI
- Kurusawa, 2020, Chemically Defined, High-Density Insect Cell-Based Expression System for Scalable AAV Vector Production, Mol. Ther. Methods Clin. Dev., 19, 330, 10.1016/j.omtm.2020.09.018 · DOI
- Labonte, 2016, Residue-centric Modeling and Design of Saccharide and Glycoconjugate Structures, J. Comput. Chem., 38, 276, 10.1002/jcc.24679 · DOI · Paper page
- Lajoie, 2007, Plasma Membrane Domain Organization Regulates EGFR Signaling in Tumor Cells, J. Cell Biol., 179, 341, 10.1083/jcb.200611106 · DOI · Paper page
- Lawrence, 2001, Cloning and Expression of Human Sialic Acid Pathway Genes to Generate CMP-Sialic Acids in Insect Cells, Glycoconj. J., 18, 205, 10.1023/a:1012452705349 · DOI
- Lee, 2002, Mannose Receptor-Mediated Regulation of Serum Glycoprotein Homeostasis, Science, 295, 1898, 10.1126/science.1069540 · DOI · Paper page
- Lemieux, 1999, Exploiting Differences in Sialoside Expression for Selective Targeting of MRI Contrast Reagents, J. Am. Chem. Soc., 121, 4278, 10.1021/ja984228m · doi:10.1021/ja984228m
- Li, Sialylated Immunoglobulin G: A Promising Diagnostic and Therapeutic Strategy for Autoimmune Diseases, Theranostics, 11, 5430, 10.7150/thno.53961 · DOI
- Li, 2009, Pharmacological Significance of Glycosylation in Therapeutic Proteins, Curr. Opin. Biotechnol., 20, 678, 10.1016/j.copbio.2009.10.009 · DOI · Paper page
- Li, Shotgun Scanning Glycomutagenesis: A Simple and Efficient Strategy for Constructing and Characterizing Neoglycoproteins, Proc. Natl. Acad. Sci. U. S. A., 118, e2107440118, 10.1073/pnas.2107440118 · DOI
- Li, 2017, Modulating IgG Effector Function by Fc Glycan Engineering, Proc. Natl. Acad. Sci. U. S. A., 114, 3485, 10.1073/pnas.1702173114 · DOI · Paper page
- Li, 2014, Preparation of Well-Defined Antibody–Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide–Alkyne Cycloadditions, Angew. Chem. Int. Ed. Eng., 53, 7179, 10.1002/anie.201402606 · DOI · Paper page
- Lifely, 1995, Glycosylation and Biological Activity of CAMPATH-1H Expressed in Different Cell Lines and Grown under Different Culture Conditions, Glycobiology, 5, 813, 10.1093/glycob/5.8.813 · DOI · Paper page
- Liu, 2018, Glycoengineering of Antibody (Herceptin) through Yeast Expression and In Vitro Enzymatic Glycosylation, Proc. Natl. Acad. Sci. U. S. A., 115, 720, 10.1073/pnas.1718172115 · DOI
- Liu, 2018, Pharmacokinetics of Monoclonal Antibodies and Fc-Fusion Proteins, Protein Cell, 9, 15, 10.1007/s13238-017-0408-4 · DOI · Paper page
- Liu, 2021, N-glycosylation and Enzymatic Activity of the rHuPH20 Expressed in Chinese Hamster Ovary Cells, Anal. Biochem., 632, 114380, 10.1016/j.ab.2021.114380 · DOI
- Loos, 2012, IgG-Fc Glycoengineering in Non-mammalian Expression Hosts, Arch. Biochem. Biophys., 526, 167, 10.1016/j.abb.2012.05.011 · DOI
- Lu, 2020, Development of Therapeutic Antibodies for the Treatment of Dieases, J. Biomed. Sci., 27, 1, 10.1186/s12929-019-0592-z · DOI · Paper page
- Luo, 2017, Glycoengineering of Pertuzumab and its Impact on the Pharmacokinetic/pharmacodynamic Properties, Sci. Rep., 7, 46347, 10.1038/srep46347 · DOI · Paper page
- Ma, Protein Glycoengineering: An Approach for Improving Protein Properties, Front. Chem., 8, 622, 10.3389/fchem.2020.00622 · DOI
- Ma, Protein Glycoengineering: An Approach for Improving Protein Properties, Front. Chem., 8, 622, 10.3389/fchem.2020.00622 · DOI
- Maack, 1979, Renal Filtration, Transport, and Metabolism of Low-Molecular-Weight Proteins: A Review, Kidney Int., 16, 251, 10.1038/ki.1979.128 · DOI · Paper page
- Mabashi-Asazuma, 2014, A Novel Baculovirus for the Production of Nonfucosylated Recombinant Glycoproteins in Insect Cells, Glycobiology, 24, 325, 10.1093/glycob/cwt161 · DOI
- Macdougal, 2002, Optimizing the Use of Erythropoietic Agents – Pharmacokinetic and Pharmacodynamic Considerations, Nephrol. Dial. Transpl., 17, 66, 10.1093/ndt/17.suppl_5.66 · DOI · Paper page
- Mahal, 1997, Engineering Chemical Reactivity on Cell Surfaces through Oligosaccharide Biosynthesis, Science, 276, 1125, 10.1126/science.276.5315.1125 · DOI · Paper page
- Maneval, 2020, Chapter 9 - Pegvorhyaluronidase Alfa: A PEGylated Recombinant Human Hyaluronidase PH20 for the Treatment of Cancers that Accumulate Hyaluronan
- Marchal, 2001, Glycoproteins from Insect Cells: Sialylated or Not?, Biol. Chem., 382, 151, 10.1515/BC.2001.023 · DOI · Paper page
- Martins, 2016, A Comprehensive Review of the Neonatal Fc Receptor and its Application in Drug Delivery, Pharmacol. Ther., 161, 22, 10.1016/j.pharmthera.2016.03.007 · DOI
- Mastrangeli, 2019, Glycoengineered Antibodies: towards the Next-Generation of Immunotherapeutics, Glycobiology, 29, 199, 10.1093/glycob/cwy092 · DOI
- Mathew, 2017, Glycoengineering of Esterase Activity through Metabolic Flux-Based Modulation of Sialic Acid, ChemBioChem, 18, 1204, 10.1002/cbic.201600698 · DOI
- Mathew, 2016, Metabolic Flux-Driven Sialylation Alters Internalization, Recycling, and Drug Sensitivity of the Epidermal Growth Factor Receptor (EGFR) in SW1990 Pancreatic Cancer Cells, Oncotarget, 7, 66491, 10.18632/oncotarget.11582 · DOI
- Mathew, 2012, Extracellular and Intracellular Esterase Processing of SCFA-Hexosamine Analogs: Implications for Metabolic Glycoengineering and Drug Delivery, Bioorg. Med. Chem. Lett., 22, 6929, 10.1016/j.bmcl.2012.09.017 · doi:10.1016/j.bmcl.2012.09.017
- Menacho-Melgar, 2020, Improved, Scalable, Two-Stage, Autoinduction of Recombinant Protein Expression in E. coli Using Phosphate Depletion, bioRxiv, 10.10023/bit.27440 · doi:10.10023/bit.27440
- Mertz, 2020, Comparison of Three Glycoproteomic Methods for the Analysis of the Secretome of CHO Cells Treated with 1,3,4-O-Bu3ManNAc, Bioengineering, 7, 144, 10.3390/bioengineering7040144 · DOI
- Montero-Morales, 2018, Advanced Plant-Based Glycan Engineering, Front. Bioeng. Biotechnol., 6, 81, 10.3389/fbioe.2018.00081 · DOI
- Mullard, 2021, FDA Approves 100th Monoclonal Antibody Product, Nat. Rev. Drug Discov., 20, 491, 10.1038/d41573-021-00079-7 · DOI · Paper page
- Muthana, 2009, Recent Progress in Chemical and Chemoenzymatic Synthesis of Carbohydrates, Curr. Opin. Chem. Biol., 13, 573, 10.1016/j.cbpa.2009.09.013 · doi:10.1016/j.cbpa.2009.09.013
- Nakano, 2009, Capillary Electrophoresis-Electrospray Ionization Mass Spectrometry for Rapid and Sensitive N-Glycan Analysis of Glycoproteins as 9-fluorenylmethyl Derivatives, Glycobiology, 19, 135, 10.1093/glycob/cwn115 · DOI · Paper page
- Narimatsu, 2021, Genetic Glycoengineering in Mammalian Cells, J. Biol. Chem., 296, 100448, 10.1016/j.jbc.2021.100448 · DOI
- Ning, 2010, Protein Modification by Strain-Promoted Alkyne-Nitrone Cycloaddition, Angew. Chem. Int. Ed. Eng., 49, 3065, 10.1002/anie.201000408 · DOI
- Offersen, 2020, HIV Antibody Fc N-Linked Flycosylation Is Associated with Viral Rebound, Cell Rep, 33, 103502, 10.1016/j.celrep.2020.108502 · DOI
- Okeley, 2013, Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody−drug Conjugation, Bioconjug. Chem., 24, 1650, 10.1021/bc4002695 · DOI
- Olden, 1982, Carbohydrate Moieties of Glycoproteins a Re-evaluation of Their Function, Biochim. Biophys. Acta, 650, 209, 10.1016/0304-4157(82)90017-X · DOI · Paper page
- Orlean, 2012, Architecture and Biosynthesis of the Saccharomyces cerevisiae Cell wall, Genetics, 192, 775, 10.1534/genetics.112.144485 · DOI · Paper page
- Ovacik, 2018, Tutorial on Monoclonal Antibody Pharmacokinetics and its Considerations in Early Development, Clin. Transl. Sci., 11, 540, 10.1111/cts.12567 · DOI · Paper page
- Palmberger, 2011, Insect Cells for Antibody Production: Evaluation of an Efficient Alternative, J. Biotechnol., 153, 160, 10.1016/j.jbiotec.2011.02.009 · DOI
- Pandhal, 2010, N-linked Glycoengineering for Human Therapeutic Proteins in Bacteria, Biotechnol. Lett., 32, 1189, 10.1007/s10529-010-0289-6 · DOI
- Pereira, 2018, The "Less-Is-More" in Therapeutic Antibodies: Afucosylated Anti-cancer Antibodies with Enhanced Antibody-Depedent Cellular Cytotoxicity, MAbs, 10, 693, 10.1080/19420862.2018.1466767 · DOI · Paper page
- Peters, 1976, Reactivity of the Sialic Acid Derivative 5-Acetamido-3,5-Dideoxy-L-Arabino-Heptulosonic Acid in the Resorcinol and Thiobarbituric Acid Assays, Carbohydr. Res., 47, 345, 10.1016/s0008-6215(00)84204-4 · doi:10.1016/s0008-6215(00)84204-4
- Pindel, 1997, Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase that Catalyzes the Hydrolysis of Cocaine and Heroin, J. Biol. Chem., 272, 14769, 10.1074/jbc.272.23.14769 · DOI · Paper page
- Pratama, 2021, Genetic and Process Engineering Strategies for Enhanced Recombinant N-Glycoprotein Production in Bacteria, Microb. Cell Fact., 20, 198, 10.1186/s12934-021-01689-x · DOI
- Prescher, 2003, Probing Azido Sugar Metabolism In Vivo Using the Staudinger Ligation, Glycobiology, 13, 894
- Pucić, 2011, High Throughput Isolation and Glycosylation Analysis of IgG-Variability and Heritability of the IgG Glycome in Three Isolated Human Populations, Mol. Cell. Proteomics, 10, M111, 10.1074/mcp.M111.010090 · DOI · Paper page
- Qasba, 2015, Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltranserases, Bioconjug. Chem., 26, 2170, 10.1021/acs.bioconjchem.5b00173 · DOI
- Qun, 2019, The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins, J. Pharm. Sci., 108, 1366, 10.1016/j.xphs.2018.11.029 · DOI · Paper page
- Rosales-Mendoza, 2015, Implications of Plant Glycans in the Development of Innovative Vaccines, Expert Rev. Vaccin., 15, 915, 10.1586/14760584.2016.1155987 · DOI
- Roseman, 2000, Molecular Basis of Lutropin Recognition by mannose/GalNAc-4-SO4 Receptor, Proc. Natl. Acad. Sci. U. S. A., 94, 9949, 10.1073/pnas.170184597 · DOI · Paper page
- Rup, 2017, Immunogenicity of Glycans on Biotherapeutic Drugs Produced in Plant Expression Systems - the Taliglucerase Alfa story, PLoS One, 12, e0186211, 10.1371/journal.pone.0186211 · DOI
- Ryman, 2017, Pharmacokinetics of Monoclonal Antibodies, CPT Pharmacometrics Syst. Pharmacol., 6, 576, 10.1002/psp4.12224 · DOI · Paper page
- Saeui, 2020, Cell Line-, Protein-, and Sialoglycosite-specific Control of Flux-Based Sialylation in Human Breast Cells: Implications for Cancer Progression, Front. Chem., 8, 13, 10.3389/fchem.2020.00013 · DOI
- Saez-Valero, 2000, Altered Glycosylation of Acetylcholinesterase in Lumbar Cerebrospinal Fluid of Patients with Alzheimer's Disease, J. Neurol. Neurosurg. Psych., 69, 664, 10.1136/jnnp.69.5.664 · DOI
- Sampathkumar, 2006, Metabolic Installation of Thiols into Sialic Acid Modulates Adhesion and Stem Cell Biology, Nat. Chem. Biol., 2, 149, 10.1038/nchembio770 · DOI
- Samraj, 2015, A Red Meat-Derived Glycan Promotes Inflammation and Cancer Progression, Proc. Natl. Acad. Sci. U. S. A., 112, 542, 10.1073/pnas.1417508112 · DOI · Paper page
- Sanchez-Garcia, 2016, Recombinant Pharmaceuticals from Microbial Cells: a 2015 Update, Microb. Cell Fact., 15, 33, 10.1186/s12934-016-0437-3 · DOI · Paper page
- Sarkar, 1995, Disaccharide Uptake and Priming in Animal Cells: Inhibition of Sialyl Lewis X by Acetylated Gal β1,4GalNAc B-Onaphthalenemethanol, Proc. Natl. Acad. Sci. U. S. A., 92, 3323, 10.1073/pnas.92.8.3323 · DOI · Paper page
- Sato, 1993, Binding, Internalization, and Degradation of Mannose-Terminated Glucocerebrosidase by Macrophages, J. Clin. Invest., 91, 1909, 10.1172/JCI116409 · DOI
- Sawa, 2006, Glycoproteomic Probes for Fluorescent Imaging of Fucosylated Glycans In Vivo, Proc. Natl. Acad. Sci. U. S. A., 103, 12371, 10.1073/pnas.0605418103 · DOI · Paper page
- Saxon, 2000, Cell Surface Engineering by a Modified Staudinger Reaction, Science, 287, 2007, 10.1126/science.287.5460.2007 · DOI · Paper page
- Schillberg, 2019, Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins, Front. Plant Sci., 10, 720, 10.3389/fpls.2019.00720 · DOI · Paper page
- Schneider, 2013, Expression of Human Butyrylcholinesterase with an Engineered Glycosylation Profile Resembling the Plasma-Derived Orthologue, Biotechnol. J., 9, 501, 10.1002/biot.201300229 · DOI
- Schwartz, 1984, The Hepatic Asialoglycoprotein Receptor, CRC Crit. Rev. Biochem., 16, 207, 10.3109/10409238409108716 · DOI · Paper page
- Seabright, 2019, Protein and Glycan Mimicry in HIV Vaccine Design, J. Mol. Biol., 431, 2223, 10.1016/j.jmb.2019.04.016 · DOI
- Semerano, 2009, Les anticorps dans les maladies immunes inflammatooires chroniques, Med. Sci. (Paris)., 25, 1108, 10.1051/medsci/200925121108 · doi:10.1051/medsci/200925121108
- Senger, 2009, Enhanced Papillomavirus-like Particle Production in Insect Cells, Virology, 388, 344, 10.1016/j.virol.2009.04.004 · DOI
- Shaaltiel, 2007, Production of Glucocerebrosidase with Terminal Mannose Glycans for Enzyme Replacement Therapy of Gaucher's Disease Using a Plant Cell System, Plant Biotechnol. J., 5, 579, 10.1111/j.1467-7652.2007.00263.x · DOI · Paper page
- Sheikh, 2000, Endo 180, an Endocytic Recycling Glycoportein Related to the Macrophage Mannose Receptor Is Expressed on Fibroblasts, Endothelial Cells and Macrophages and Functions as a Lectin Receptor, J. Cell Sci., 113, 1021, 10.1242/jcs.113.6.1021 · DOI · Paper page
- Shi, 2006, Anti-influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel, J. Pharmacol. Exp. Ther., 19, 1477, 10.1124/jpet.106.111807 · DOI
- Shuster, 2002, Hyaluronidase Reduces Human Breast Cancer Xenografts in SCID Mice, Int. J. Cancer, 102, 192, 10.1002/ijc.10668 · DOI · Paper page
- Singh, 20152015, Impact of Hybrid and Complex N-Glycans on Cell Surface Targeting of the Endogenous Chloride Cotransporter Slc12a2, Int. J. Cell Biol., 505294, 10.1155/2015/505294 · DOI
- Singh, 2016, Microbial Enzymes: Industrial Progress in 21st century, 3 Biotech., 6, 174, 10.1007/s13205-016-0485-8 · DOI · Paper page
- Song, 2013, Strategic Addition of an N-Linked Glycan to a Monoclonal Antibody Improves its HIV-1–Neutralizing Activity, Nat. Biotechnol., 31, 1047, 10.1038/nbt.2677 · DOI
- Stabach, 2021, Improving the Pharmacodynamics and In Vivo Activity of ENPP1-Fc through Protein and Glycosylation Engineering, Clin. Transl. Sci., 14, 362, 10.1111/cts.12887 · DOI
- Stanley, 2005, Chinese Hamster Ovary (CHO) Glycosylation Mutants for Glycan Engineering, 371
- Stanley, 1996, CHO Cells Provide Access to Novel N-Glycans and Developmentally Regulated Glycosyltransferases, Glycobiology, 6, 696, 10.1093/glycob/6.7.695 · DOI
- Steinke, 2015, The Alpha Gal story: Lessons Learned from Connecting the Dots, J. Allergy Clin. Immunol., 135, 589, 10.1016/j.jaci.2014.12.1947 · DOI · Paper page
- Sudo, 2014, Different IVIG Glycoforms Affect In Vitro Inhibition of Anti-ganglioside Antibody-Mediated Complement Deposition, PLoS One, 9, e017772, 10.1371/journal.pone.0107772 · DOI
- Sukenik, 2018, Transient Recombinant Protein Production in Glycoengineered Nicotiana Benthamiana Cell Suspension Culture, Int. J. Mol. Sci., 19, 1205, 10.3390/ijms19041205 · DOI
- Szolnoky, 2001, A Mannose-Binding Receptor Is Expressed on Human Keratinocytes and Mediates Killing of Candida Albicans, J. Investig. Dermatol., 117, P205, 10.1046/j.1523-1747.2001.14071.x · DOI
- Szymanski, 2002, Evidence for a System of General Protein Glycosylation in Campylobacter Jejuni, Mol. Microbiol., 32, 1022, 10.1046/j.1365-2958.1999.01415.x · DOI · Paper page
- Tang, 2019, Homogeneous Antibody-Drug Conjugates via Glycoengineering, Methods Mol. Biol., 2033, 221, 10.1007/978-1-4939-9654-4_15 · DOI
- Tariq, 2018, Glycosylation of Recombinant Anticancer Therapeutics in Different Expression Systems with Emerging Technologies, Cancer Res., 78, 2787, 10.1158/0008-5472.can-18-0032 · DOI
- Tekoah, 2013, Glycosylation and Functionality of Recombinant B-Glycocerebrosidase from Various Production Systems, Biosci. Rep., 33, e00071, 10.1042/BSR20130081 · DOI · Paper page
- Tibbitts, 2016, Key Factors Influencing ADME Properties of Therapeutic Proteins: A Need for ADME Characterization in Drug Discovery and Development, MAbs, 8, 229, 10.1080/19420862.2015.1115937 · DOI · Paper page
- Tong, 2003, Glycosylation Changes as Markers for the Diagnosis and Treatment of Human Disease, 199
- Top, 2019, Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems, Front. Plant Sci., 10, 261, 10.3389/fpls.2019.00261 · DOI
- Torres-Pérez, 2020, Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery, Front. Oncol., 10, 605037, 10.3389/fonc.2020.605037 · DOI
- Toth, 2014, A New Insect Cell Glycoengineering Approach Provides Baculovirus-Inducible Glycogene Expression and Increases Human-type Glycosylation Efficiency, J. Biotechnol., 19, 10.1016/j.jbiotec.2014.04.011 · DOI
200 of 233 shown
Cited by
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Metadata
- Authors
- Dammen-Brower, K., Epler, P., Zhu, S., Bernstein, Z. J., Stabach, P. R., Braddock, D. T., Spangler, J. B., & Yarema, K. J.
- Venue
- Frontiers in Chemistry
- Publisher
- Frontiers Media SA
- Published
- 2022-04-13
- Volume
- 10
- Pages
- 863118-863118
- ISSN
- 2296-2646 (ISSN-L)
- OpenAlex
- W4224022140
- Cited by
- 62
- References
- 27
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategies for Glycoengineering Therapeutic Proteins. https://app.cochat.ai/papers/10.3389/fchem.2022.863118
- The paper
- Dammen-Brower, K., Epler, P., Zhu, S., Bernstein, Z. J., Stabach, P. R., Braddock, D. T., Spangler, J. B., & Yarema, K. J. (2022). Strategies for Glycoengineering Therapeutic Proteins. Frontiers in Chemistry. https://doi.org/10.3389/fchem.2022.863118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.